Although a significant effect was observed that indicated an improvement in the mean percent change in all parameters 3 months after treatment (serum Lf level, serum glutathione-S-transferase enzyme (GST) activity, IFN-γ level, tumor marker carcinoembryonic antigen (CEA), renal and hepatic function tests, and complete blood counts), no significant difference was observed between the results from patients in the test group and in the control group (Moastafa et al., 2014). The gene discussed is IFNG; the disease is neoplasm.